Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

ABSTRACT: Therapeutic options for multiple sclerosis (MS) have significantly increased over the last few years. T lymphocytes are considered to play a central role in initiating and perpetuating the pathological immune response. Currently approved therapies for MS target T lymphocytes, either in an unspecific manner or directly by interference with specific T-cell pathways. While the concept of "T-cell-specific therapy" implies specificity and selectivity, currently approved approaches come from a general shaping of the immune system towards anti-inflammatory immune responses by non-T-cell-selective immune suppression or immune modulation (e.g., interferons-immune modulation approach) to a depletion of immune cell populations involving T cells (e.g., anti-CD52, alemtuzumab-immune selective depletion

SUBMITTER: Bittner S 

PROVIDER: S-EPMC4720668 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature